StreetInsider.com News Articles

Form 144 Atara Biotherapeutics, Filed by: Nguyen AnhCo

Wed, 26 Aug 2026 19:47:00 -0400

si-local-file:///var/storage/secattach/20260826/26983228.html

Form 144 Atara Biotherapeutics, Filed by: Nguyen AnhCo

Wed, 26 Aug 2026 19:47:00 -0400

si-local-file:///var/storage/secattach/20260826/26983228.html

Form 4 Atara Biotherapeutics, For: Aug 17 Filed by: Nguyen AnhCo

Wed, 26 Aug 2026 19:46:00 -0400

si-local-file:///var/storage/secattach/20260826/26983224.html

Form 4 Atara Biotherapeutics, For: Aug 17 Filed by: Nguyen AnhCo

Wed, 26 Aug 2026 19:46:00 -0400

si-local-file:///var/storage/secattach/20260826/26983224.html

TD Cowen Assumes Atara Biotherapeutics (ATRA) at Buy

Sat, 22 Aug 2026 07:54:54 -0400

TD Cowen analyst Phil Nadeau assumes coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Buy rating.

For an analyst ratings summary and ratings history on Atara Biotherapeutics click here. For more ratings news on Atara Biotherapeutics click here.

Shares of Atara Biotherapeutics closed at $9.70 yesterday.

Form SCHEDULE 13G/A Atara Biotherapeutics, Filed by: Point72 Asset Management, L.P.

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930351.html

Form SCHEDULE 13G/A Atara Biotherapeutics, Filed by: Point72 Asset Management, L.P.

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930351.html

Form 10-Q Atara Biotherapeutics, For: Jun 30

Wed, 12 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26913126.html

Form 10-Q Atara Biotherapeutics, For: Jun 30

Wed, 12 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26913126.html

ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 10c

Wed, 12 Aug 2026 16:14:49 -0400

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.32), $0.10 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $630 thousand versus the consensus estimate of $2.55 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

Form 8-K Atara Biotherapeutics, For: Aug 12

Wed, 12 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260812/26912931.html

Form 8-K Atara Biotherapeutics, For: Aug 12

Wed, 12 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260812/26912931.html

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Wed, 12 Aug 2026 16:05:00 -0400

Productive Type A Meeting with FDA for tabelecleucel

FDA guidance provided on resubmission of tabelecleucel BLA

Year over Year costs and operating expenses reduction of 87%

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026 and business updates.

“This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Wed, 12 Aug 2026 16:05:00 -0400

Productive Type A Meeting with FDA for tabelecleucel

FDA guidance provided on resubmission of tabelecleucel BLA

Year over Year costs and operating expenses reduction of 87%

“This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Wed, 12 Aug 2026 16:05:00 -0400

Productive Type A Meeting with FDA for tabelecleucel

FDA guidance provided on resubmission of tabelecleucel BLA

Year over Year costs and operating expenses reduction of 87%

“This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Wed, 12 Aug 2026 16:05:00 -0400

Productive Type A Meeting with FDA for tabelecleucel

FDA guidance provided on resubmission of tabelecleucel BLA

Year over Year costs and operating expenses reduction of 87%

“This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Wed, 12 Aug 2026 16:05:00 -0400

Productive Type A Meeting with FDA for tabelecleucel

FDA guidance provided on resubmission of tabelecleucel BLA

Year over Year costs and operating expenses reduction of 87%

“This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Wed, 12 Aug 2026 16:05:00 -0400

Productive Type A Meeting with FDA for tabelecleucel

FDA guidance provided on resubmission of tabelecleucel BLA

Year over Year costs and operating expenses reduction of 87%

“This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Wed, 12 Aug 2026 16:05:00 -0400

Productive Type A Meeting with FDA for tabelecleucel

FDA guidance provided on resubmission of tabelecleucel BLA

Year over Year costs and operating expenses reduction of 87%

“This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Wed, 12 Aug 2026 16:05:00 -0400

Productive Type A Meeting with FDA for tabelecleucel

FDA guidance provided on resubmission of tabelecleucel BLA

Year over Year costs and operating expenses reduction of 87%

“This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with

Form 4 Atara Biotherapeutics, For: Jul 22 Filed by: Redmile Group, LLC

Fri, 24 Jul 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260724/26814560.html

Form 4 Atara Biotherapeutics, For: Jul 22 Filed by: Redmile Group, LLC

Fri, 24 Jul 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260724/26814560.html

Form SCHEDULE 13D/A Atara Biotherapeutics, Filed by: Redmile Group, LLC

Fri, 24 Jul 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260724/26814544.html

Form SCHEDULE 13D/A Atara Biotherapeutics, Filed by: Redmile Group, LLC

Fri, 24 Jul 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260724/26814544.html

Form 3 Atara Biotherapeutics, For: Jun 26 Filed by: Sarney Kevin G

Mon, 06 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260706/26735642.html